Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -754,626 | -574,234 | -365,277 | -165,271 | -642,178 |
| Depreciation Amortization | 30,459 | 22,254 | 15,496 | 7,584 | 30,107 |
| Income taxes - deferred | N/A | 0 | N/A | N/A | -2,225 |
| Accounts receivable | -2,923 | 4,641 | 6,045 | 1,714 | 13,900 |
| Accounts payable and accrued liabilities | -1,182 | -12,315 | 9,636 | -7,964 | -15,057 |
| Other Working Capital | -63,777 | -34,259 | -38,162 | -64,262 | 61,424 |
| Other Operating Activity | 156,607 | 124,574 | 66,913 | 31,737 | 126,443 |
| Operating Cash Flow | $-635,442 | $-469,339 | $-305,349 | $-196,462 | $-427,586 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -38,054 | -23,626 | -12,796 | -3,110 | -23,496 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -87,422 |
| Purchase Of Investment | -1,234,719 | -774,530 | -321,252 | -42,022 | -1,186,022 |
| Sale Of Investment | 1,284,806 | 979,791 | 518,141 | 184,274 | 788,263 |
| Other Investing Activity | -4,732 | -4,639 | -4,683 | -380 | -55 |
| Investing Cash Flow | $7,301 | $176,996 | $179,410 | $138,762 | $-508,732 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 391,645 | N/A | N/A | 149,902 |
| Common Stock Issued | 33,434 | 23,987 | 17,137 | 7,664 | 849,235 |
| Other Financing Activity | 391,623 | -22 | -22 | -22 | -131 |
| Financing Cash Flow | $425,057 | $415,610 | $17,115 | $7,642 | $999,006 |
| Exchange Rate Effect | -377 | -24 | -226 | -53 | -5,145 |
| Beginning Cash Position | 446,658 | 446,658 | 446,658 | 446,658 | 389,115 |
| End Cash Position | 243,197 | 569,901 | 337,608 | 396,547 | 446,658 |
| Net Cash Flow | $-203,461 | $123,243 | $-109,050 | $-50,111 | $57,543 |
| Free Cash Flow | |||||
| Operating Cash Flow | -635,442 | -469,339 | -305,349 | -196,462 | -427,586 |
| Capital Expenditure | -38,054 | -23,626 | -12,796 | -3,110 | -23,496 |
| Free Cash Flow | -673,496 | -492,965 | -318,145 | -199,572 | -451,082 |